An observational study in Prurigo Nodularis (PN), sponsored by UMC Utrecht. Recruiting at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-18.
Sponsored by UMC Utrecht · Observational
With the arrival of dupilumab as the first available targeted therapy for PN, there is an unmet need for real-world data and translational research on the working mechanism of dupilumab on PN, to optimize individualized targeted treatment.
UMC Utrecht is the lead sponsor of 350 studies on the registry; 80 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Secondary and tertiary care clinics
Exclusion Criteria:
In the Netherlands, the standard care for patients with moderate-to-severe prurigo nodularis who have failed or are contraindicated to conventional systemic immunosuppressive treatments consists of 300 mg of dupilumab administered subcutaneously every two weeks, following a loading dose of 600 mg administered subcutaneously.
Also known as: Dupixent
Peak Pruritus NRS (PP-NRS)
Peak pruritus NRS of the past 24 hours
Time frame: From enrollment to 52 weeks of treatment
Investigator Global Assessment scale of Prurigo Nodularis stage (IGA-PN)
Investigator Global Assessment scale of Prurigo Nodularis stage
Time frame: From enrollment to 52 weeks of treatment
Drug survival
Duration of dupilumab treatment, reasons for discontinuation
Time frame: From enrollment to 52 weeks of treatment
Adverse events
Data on the incidence, severity, relation to dupilumab and clinical consequences of adverse events
Time frame: From enrollment to 52 weeks of treatment
Skin homing T cell subtypes
Time frame: Up to 52 weeks of treatment
Serum levels of relevant proteins
Time frame: Up to 52 weeks of treatment
Systemic epigenetic changes
Time frame: Up to 52 weeks of treatment
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
UMC Utrecht